BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12832740)

  • 1. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.
    Sheashaa HA; Bakr MA; Ismail AM; Sobh MA; Ghoneim MA
    J Nephrol; 2003; 16(3):393-8. PubMed ID: 12832740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study.
    Sheashaa HA; Bakr MA; Ismail AM; Gheith OE; El-dahshan KF; Sobh MA; Ghoneim MA
    Am J Nephrol; 2005; 25(3):221-5. PubMed ID: 15908741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year follow-up of basiliximab induction therapy for live-donor kidney transplant: a prospective randomized controlled study.
    Sheashaa HA; Bakr MA; Rashad RH; Ismail AM; Sobh MA; Ghoneim MA
    Exp Clin Transplant; 2011 Aug; 9(4):247-51. PubMed ID: 21819369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study.
    Sheashaa HA; Bakr MA; Ismail AM; Mahmoud KM; Sobh MA; Ghoneim MA
    Clin Exp Nephrol; 2008 Oct; 12(5):376-381. PubMed ID: 18327678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD; Rajagopalan PR; Hall M
    Transplantation; 1999 Jan; 67(2):276-84. PubMed ID: 10075594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
    Ponticelli C; Yussim A; Cambi V; Legendre C; Rizzo G; Salvadori M; Kahn D; Kashi H; Salmela K; Fricke L; Heemann U; Garcia-Martinez J; Lechler R; Prestele H; Girault D;
    Transplantation; 2001 Oct; 72(7):1261-7. PubMed ID: 11602853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
    Lee BM; Oh CK; Jin SH; Kim JH; Kim SJ; Kim H; Shin GT
    Transplant Proc; 2006 Sep; 38(7):2025-8. PubMed ID: 16979988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
    Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
    Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
    Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J; Yang S; Wu W
    Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M; Ming A; Zhao M
    Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-implantation basiliximab reduces incidence of early acute rejection in pediatric heart transplantation.
    Grundy N; Simmonds J; Dawkins H; Rees P; Aurora P; Burch M
    J Heart Lung Transplant; 2009 Dec; 28(12):1279-84. PubMed ID: 19864164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
    J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.